IMACOR INC

Capabilities

ImaCor's Hemodynamic Ultrasound Platform combines imaging and monitoring in a portable package for ease-of-use by high acuity care teams. The result --- lifesaving course corrections in as much as 70% of patients vs standard of care. ImaCor’s miniaturized transesophageal ultrasound probe, the ClariTEE, is FDA approved to be left in place for up to 72 hours, enabling direct visualization in the ICU of cardiac filling and function over time. The patented probe has been used in over 20,000 patients with no complications. ImaCor’s Hemodynamic Ultrasound Platform provides preload and contractility data for rapid decision making, transforming care for sepsis, surgery, and cardiac support patients.